19 Fluorine ‐ MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer
Journal of Magnetic Resonance Imaging · 2025
DOI: 10.1002/jmri.29589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Magnetic Resonance Imaging, 2025. Verfasst von Wilfried Reichardt und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Physics, Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, Unive…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Microenvironment, Fluorine-19 Magnetic Resonance Imaging, Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Krebshilfe, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Background
Pancreatic cancer has a poor prognosis. Targeting Kirsten Rat Sarcoma (KRAS) mutation and its related pathways may enhance immunotherapy efficacy. While in vivo monitoring of therapeutic response and immune cell migration remains challenging, Fluorine‐19 MRI ( 19 F MRI) may allow noninvasive longitudinal imaging of immune cells.
Purpose
Evaluating the potential of 19 F MRI for monitoring changes in the tumor immune microenvironment, in response to combined SHP2/MEK inhibition. Study Type Pre‐clinical animal study. Animal Model Murine genetically engineered pancreatic cancer model (N = 20, both sexes). Field Strength/Sequence 9.4‐T, two‐dimensional multi‐slice Rapid Acquisition with Relaxation Enhancement sequence. Intravenous injection of 19 F‐perfluorocarbon (PFC) nanoparticles. Assessment Upon tumor detection by conventional 1 H MRI screening, 19 F MRI was performed in mice 24 hours after PFC nanoparticle administration. Animals were randomly assigned to four treatment groups: allosteric Src‐homology‐2‐containing protein tyrosine phosphatase 2 (SHP2) inhibitor SHP099, the mitogen‐activated extracellular signal‐regulated kinase 1/2 (MEK1/2) inhibitor Trametinib, the combination of both, or a vehicle control (4 to 6 mice each group), administered every other day per oral gavage. 1 H and 19 F MRI was repeated 7 days and 14 days later. Pancreatic immune cell infiltrates were analyzed by flow cytometry and multiplex immunohistofluorescence (mIHF) upon sacrifice. Statistical Tests Independent t ‐tests and one‐way analysis of variance.
Results
19 F MRI revealed continuous decrease of PFC‐signals in tumors from vehicle controls (100%, 80%, and 74% on days 0, 7, and 14, respectively), contrasting with stable or increasing signals under KRAS‐pathway‐directed treatment. MEK inhibition showed 100%, 152%, and 84% and dual SHP2/MEK1/2 inhibition demonstrated signals of 100%, 134%, and 100% on days 0, 7, 14, respectively. mIHF analyses indicated CD11b + macrophages/monocytes as primary contributors to the observed 19 F MRI signal differences. Data Conclusion 19 F MRI might provide non‐invasive longitudinal estimates for abundance and spatial distribution of CD11b + macrophages/monocytes in pancreatic cancer. Evidence Level 1 Technical Efficacy Stage 2
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Physics, Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.
- German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
ORCID-Profile: Solène Besson, Dietrich A Ruess
Förderung
- Deutsche Krebshilfe
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Reichardt, W., Gewalt, T., Hafner, P., Keller, S. J., Chen, X., Alrawashdeh, A., Li, Y., Besson, S., Fichtner-Feigl, S., von Elverfeldt, D., Jumaa, H., & Ruess, D. A. (2025). 19 Fluorine ‐ MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29589
Vancouver
Reichardt W, Gewalt T, Hafner P, Keller SJ, Chen X, Alrawashdeh A, et al. 19 Fluorine ‐ MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer. Journal of Magnetic Resonance Imaging. 2025. doi:10.1002/jmri.29589
BibTeX
@article{Reichardt2025,
author = {Reichardt, Wilfried and Gewalt, Tabea and Hafner, Philipp and Keller, Steffen J and Chen, Xun and Alrawashdeh, Asma and Li, Yayu and Besson, Solène and Fichtner-Feigl, Stefan and von Elverfeldt, Dominik and Jumaa, Huda and Ruess, Dietrich A},
title = {19 Fluorine ‐ MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer},
journal = {Journal of Magnetic Resonance Imaging},
year = {2025},
doi = {10.1002/jmri.29589}
}
EUVIMED